Blueprint Medicines

150 articles about Blueprint Medicines

• Blueprint Medicines Reports Fourth Quarter and Full Year 2017 Financial Results

  2/21/2018

  Blueprint Medicines Corporation, a leader in discovering and developing targeted kinase medicines for patients with genomically defined diseases, today reported financial results and provided a business update for the fourth quarter and full year ended December 31, 2017.

• Blueprint Medicines to Report Fourth Quarter and Full Year 2017 Financial Results on Wednesday, February 21, 2018

  2/16/2018

  The archived webcast will be available on Blueprint Medicines' website approximately two hours after the conference call and will be available for 30 days following the call.

• Blueprint Medicines, Corp. Announces Pricing of Public Offering of Shares of Common Stock

  12/13/2017

  Blueprint Medicines today announced the pricing of an underwritten public offering of 3,703,704 shares of its common stock at a public offering price of $81.00 per share, before underwriting discounts and commissions.

• Blueprint Medicines Corp. Announces Proposed Public Offering of Shares of Common Stock

  12/12/2017

  Blueprint Medicines today announced that it has commenced an underwritten public offering of $275,000,000 in shares of its common stock.

• 

  ASH Burns Bright With Excitement

  12/12/2017

  A look at some of the exciting data clinicians and investors got to feast on from ASH.

• Blueprint Medicines Announces New Data From Ongoing Phase I Clinical Trial of Avapritinib (BLU-285) in Patients with Advanced Systemic Mastocytosis Showing Evidence of Strong Clinical Activity

  12/11/2017

  The new data from the dose escalation portion of the Phase I trial showed strong clinical activity regardless of advanced SM subtype, prior treatment with midostaurin or the presence of additional mutations.

• Blueprint Medicines Announces New Data From Ongoing Phase I Clinical Trial of BLU-285 in Patients With Advanced Gastrointestinal Stromal Tumors Showing Strengthened Clinical Activity Across Spectrum of KIT and Pdgfrα Genotypes

  11/10/2017

  The data confirm and build upon data previously presented for BLU-285 in patients with advanced GIST, demonstrating robust clinical activity and a favorable safety profile.

• Blueprint Announces Appointment Of Christopher Murray, Ph.D. As Senior Vice President, Technical Operations

  10/11/2017

• Alexion Redefines R&D Strategy, Discontinues Programs and Kills Deals With Moderna, Blueprint and Arbutus Biopharma

  7/28/2017

• Booming Blueprint to Expand Into Former GlaxoSmithKline Site

  5/5/2017